Literature DB >> 26713112

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.

Chudi O Ndubaku1, James J Crawford1, Joy Drobnick1, Ignacio Aliagas1, David Campbell2, Ping Dong3, Laura M Dornan1, Sergio Duron2, Jennifer Epler1, Lewis Gazzard1, Christopher E Heise1, Klaus P Hoeflich1, Diana Jakubiak1, Hank La1, Wendy Lee1, Baiwei Lin1, Joseph P Lyssikatos1, Jasna Maksimoska4, Ronen Marmorstein4, Lesley J Murray1, Thomas O'Brien1, Angela Oh1, Sreemathy Ramaswamy1, Weiru Wang1, Xianrui Zhao1, Yu Zhong1, Elizabeth Blackwood1, Joachim Rudolph1.   

Abstract

Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pK a and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.

Entities:  

Keywords:  Kinase inhibitor; hERG; oncology; pKa

Year:  2015        PMID: 26713112      PMCID: PMC4677365          DOI: 10.1021/acsmedchemlett.5b00398

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  Impact of lipophilic efficiency on compound quality.

Authors:  Akos Tarcsay; Kinga Nyíri; György M Keseru
Journal:  J Med Chem       Date:  2012-01-24       Impact factor: 7.446

Review 2.  Tuning out of hERG.

Authors:  Alex M Aronov
Journal:  Curr Opin Drug Discov Devel       Date:  2008-01

3.  Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Authors:  Brion W Murray; Chuangxing Guo; Joseph Piraino; John K Westwick; Cathy Zhang; Jane Lamerdin; Eleanor Dagostino; Daniel Knighton; Cho-Ming Loi; Michael Zager; Eugenia Kraynov; Ian Popoff; James G Christensen; Ricardo Martinez; Susan E Kephart; Joseph Marakovits; Shannon Karlicek; Simon Bergqvist; Tod Smeal
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

Review 4.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

5.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.

Authors:  Christy C Ong; Adrian M Jubb; Peter M Haverty; Wei Zhou; Victoria Tran; Tom Truong; Helen Turley; Tom O'Brien; Domagoj Vucic; Adrian L Harris; Marcia Belvin; Lori S Friedman; Elizabeth M Blackwood; Hartmut Koeppen; Klaus P Hoeflich
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

6.  Inhibitors of p21-activated kinases (PAKs).

Authors:  Joachim Rudolph; James J Crawford; Klaus P Hoeflich; Weiru Wang
Journal:  J Med Chem       Date:  2014-12-03       Impact factor: 7.446

Review 7.  Applications of Fluorine in Medicinal Chemistry.

Authors:  Eric P Gillis; Kyle J Eastman; Matthew D Hill; David J Donnelly; Nicholas A Meanwell
Journal:  J Med Chem       Date:  2015-07-22       Impact factor: 7.446

8.  Tuning HERG out: antitarget QSAR models for drug development.

Authors:  Rodolpho C Braga; Vinicius M Alves; Meryck F B Silva; Eugene Muratov; Denis Fourches; Alexander Tropsha; Carolina H Andrade
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

9.  Toward the development of chemoprevention agents (III): synthesis and anti-inflammatory activities of a new class of 5-glycylamino-2-substituted-phenyl-1,3-dioxacycloalkanes.

Authors:  Lanrong Bi; Ming Zhao; Keli Gu; Chao Wang; Jingfang Ju; Shiqi Peng
Journal:  Bioorg Med Chem       Date:  2007-11-12       Impact factor: 3.641

10.  Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Authors:  Christy C Ong; Sarah Gierke; Cameron Pitt; Meredith Sagolla; Christine K Cheng; Wei Zhou; Adrian M Jubb; Laura Strickland; Maike Schmidt; Sergio G Duron; David A Campbell; Wei Zheng; Seameen Dehdashti; Min Shen; Nora Yang; Mark L Behnke; Wenwei Huang; John C McKew; Jonathan Chernoff; William F Forrest; Peter M Haverty; Suet-Feung Chin; Emad A Rakha; Andrew R Green; Ian O Ellis; Carlos Caldas; Thomas O'Brien; Lori S Friedman; Hartmut Koeppen; Joachim Rudolph; Klaus P Hoeflich
Journal:  Breast Cancer Res       Date:  2015-04-23       Impact factor: 6.466

View more
  23 in total

Review 1.  Structure, biochemistry, and biology of PAK kinases.

Authors:  Rakesh Kumar; Rahul Sanawar; Xiaodong Li; Feng Li
Journal:  Gene       Date:  2016-12-19       Impact factor: 3.688

2.  MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Authors:  Christina M Knippler; Motoyasu Saji; Neel Rajan; Kyle Porter; Krista M D La Perle; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

3.  Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

Authors:  William McCoull; Edward J Hennessy; Kevin Blades; Claudio Chuaqui; James E Dowling; Andrew D Ferguson; Frederick W Goldberg; Nicholas Howe; Christopher R Jones; Paul D Kemmitt; Gillian Lamont; Jeffrey G Varnes; Richard A Ward; Bin Yang
Journal:  ACS Med Chem Lett       Date:  2016-09-14       Impact factor: 4.345

Review 4.  Targeting PAK1.

Authors:  Galina Semenova; Jonathan Chernoff
Journal:  Biochem Soc Trans       Date:  2017-02-08       Impact factor: 5.407

Review 5.  Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how.

Authors:  Yan Wang; Fuzheng Guo
Journal:  Biol Rev Camb Philos Soc       Date:  2021-11-22

6.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

Authors:  Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-03-30       Impact factor: 5.858

7.  PAK4 crystal structures suggest unusual kinase conformational movements.

Authors:  Eric Y Zhang; Byung Hak Ha; Titus J Boggon
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-10-07       Impact factor: 3.036

8.  The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.

Authors:  Tatiana Y Prudnikova; Jonathan Chernoff
Journal:  Small GTPases       Date:  2016-07-18

9.  PAK1 Positively Regulates Oligodendrocyte Morphology and Myelination.

Authors:  Tanya L Brown; Hirokazu Hashimoto; Lisbet T Finseth; Teresa L Wood; Wendy B Macklin
Journal:  J Neurosci       Date:  2021-01-21       Impact factor: 6.709

Review 10.  Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.

Authors:  Julian Blagg; Paul Workman
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.